{
    "abstract": "Hyperlipidemia is one of the main causes of aggravated hepatic ischemia-reperfusion injury (IRI). Simvastatin (SIM), a lipid-lowering drug, has been shown to effectively alleviate IRI caused by hyperlipidemia. However, the regulatory mechanism by which SIM alleviates hyperlipidemia-induced hepatic IRI is still not clear. This study aims to explore the potential mechanisms of SIM in inhibiting hyperlipidemia-induced hepatic IRI, providing new therapeutic strategies for the alleviation of hepatic IRI.\nAn animal model of hyperlipidemia was induced by feeding mice a high-fat diet for 8 weeks. Subsequently, a hepatic IRI animal model of hyperlipidemia was established by occluding the hepatic artery and portal vein for one hour, followed by reperfusion for 6 or 12 h. Enzyme linked immunosorbent assay, Western blotting, hematoxylin-eosin (H&E) staining, immunohistochemistry, immunofluorescence, and Terminal-deoxynucleoitidyl Transferase Mediated Nick End Labeling assay, were used to evaluate liver injury, neutrophil extracellular traps (NETs) formation, and related molecular mechanisms.\nHepatic IRI was accelerated by hyperlipidemia, which enhanced the expression of oxidized low-density lipoprotein (oxLDL) and Macrophage-1antigen (Mac-1), leading to the promotion of NETs formation and apoptosis of liver cells. The administration of simvastatin reduced the levels of oxLDL and Mac-1, decreased the formation of NETs, and alleviated hepatic IRI induced by hyperlipidemia.\nSimvastatin reduced hyperlipidemia-induced hepatic IRI by inhibiting the formation of NETs through the regulation of the oxLDL/Mac-1 pathway.",
    "authors": [
        {
            "affiliation": "Department of Hepatobiliary and Pancreatic Surgery, Union Shenzhen Hospital, Huazhong University of Science and Technology, 518056 Shenzhen, Guangdong, China.",
            "firstname": "Shikai",
            "initials": "S",
            "lastname": "Wang"
        },
        {
            "affiliation": "Department of Hepatobiliary and Pancreatic Surgery, Union Shenzhen Hospital, Huazhong University of Science and Technology, 518056 Shenzhen, Guangdong, China.",
            "firstname": "Zhipeng",
            "initials": "Z",
            "lastname": "Li"
        },
        {
            "affiliation": "Department of Hepatobiliary and Pancreatic Surgery, Union Shenzhen Hospital, Huazhong University of Science and Technology, 518056 Shenzhen, Guangdong, China.",
            "firstname": "Yunxiang",
            "initials": "Y",
            "lastname": "Chang"
        },
        {
            "affiliation": "Department of Hepatobiliary and Pancreatic Surgery, Union Shenzhen Hospital, Huazhong University of Science and Technology, 518056 Shenzhen, Guangdong, China.",
            "firstname": "Kai",
            "initials": "K",
            "lastname": "Dong"
        },
        {
            "affiliation": "Department of Hepatobiliary and Pancreatic Surgery, Union Shenzhen Hospital, Huazhong University of Science and Technology, 518056 Shenzhen, Guangdong, China.",
            "firstname": "Di",
            "initials": "D",
            "lastname": "He"
        },
        {
            "affiliation": "Department of Hepatobiliary and Pancreatic Surgery, Union Shenzhen Hospital, Huazhong University of Science and Technology, 518056 Shenzhen, Guangdong, China.",
            "firstname": "Xinsheng",
            "initials": "X",
            "lastname": "Cheng"
        }
    ],
    "conclusions": null,
    "copyrights": null,
    "doi": "10.24976/Discov.Med.202436187.158",
    "journal": "Discovery medicine",
    "keywords": [
        "hepatic ischemia reperfusion injury",
        "hyperlipidemia",
        "neutrophil extracellular traps (NETs)",
        "simvastatin"
    ],
    "methods": null,
    "publication_date": "2024-08-27",
    "pubmed_id": "39190387",
    "results": "Hepatic IRI was accelerated by hyperlipidemia, which enhanced the expression of oxidized low-density lipoprotein (oxLDL) and Macrophage-1antigen (Mac-1), leading to the promotion of NETs formation and apoptosis of liver cells. The administration of simvastatin reduced the levels of oxLDL and Mac-1, decreased the formation of NETs, and alleviated hepatic IRI induced by hyperlipidemia.",
    "title": "Simvastatin Inhibits the Formation of NETs by the Mac-1 Pathway to Reduce Hepatic Ischemia-Reperfusion Injury under High-Fat Conditions.",
    "xml": "<Element 'PubmedArticle' at 0x788503f74180>"
}